Jazz Pharmaceuticals Announces Conference Call and Webcast for JZP-110 Investor Update
Interested parties may access the live audio webcast and download the accompanying slide presentation from the Investors section of the company's website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
Conference Call Details:
U.S. Dial-In Number: +1 503 343 6056
Outside the U.S. Dial-In Number: +1 855 353 7924
Passcode: 29531820
A replay of the conference call will be available through
Replay U.S. Dial-In Number: +1 404 537 3406
Replay Outside the U.S. Dial-In Number: +1 855 859 2056
Passcode: 29531820
An archive of the audio webcast will be available for at least one week on the Investors section of the company's website at www.jazzpharmaceuticals.com.
About JZP-110
JZP-110 is a late-stage investigational wake-promoting agent being developed as a treatment for excessive sleepiness (ES) in adult patients with narcolepsy or with obstructive sleep apnea (OSA).
About
Logo - http://photos.prnewswire.com/prnh/20150930/272253LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-conference-call-and-webcast-for-jzp-110-investor-update-300284621.html
SOURCE
Investors, Kathee Littrell, Vice President, Investor Relations, Ireland, +353 1 634 7887, U.S., +1 650 496 2717; or Media, Laurie Hurley, Vice President, Corporate Affairs, Ireland, +353 1 634 7894, U.S., +1 650 496 2796